Avalyn Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire•12/11/2026•08:00 ET
0
Key Highlights
- ➤Cash, equivalents and marketable securities reached $386.6 million, funding operations into 2029
- ➤AP03 Phase 1 study initiated in healthy volunteers for inhaled pirfenidone-nintedanib combination
- ➤AP01 MIST Phase 2b results expected in the second half of 2027
- ➤AP02 AURA Phase 2 results anticipated in late 2027
- ➤Third-quarter net loss widened to $29.7 million from $23.6 million year over year
Expert Statements
Lyn Baranowski, Chief Executive Officer of Avalyn
“As we approach year end, I’m proud of the progress we’ve made across our portfolio and the strong foundation we’ve built for what we expect to be a transformational 2027, with data anticipated across all three of our programs”
Lyn Baranowski, Chief Executive Officer of Avalyn
“We remain confident in the potential of inhaled therapies to transform the standard of care for pulmonary fibrosis by delivering effective, well-tolerated treatments both as monotherapies and in combination.”
Lyn Baranowski, Chief Executive Officer of Avalyn
“With our monotherapy programs advancing through later stages of development, the initiation of our first-in-human study of our combination program, AP03, marks the next step in our portfolio expansion.”
Lyn Baranowski, Chief Executive Officer of Avalyn
“Backed by a strong balance sheet and dedicated team, we are well-positioned to deliver on our key milestones and continue advancing our mission to address the significant unmet needs of people living with rare respiratory diseases.”
Initiated Phase 1 study of AP03, a fixed dose combination of nebulized pirfenidone and nintedanib, in healthy volunteers
Presented new AP01 data at ERS Congress and published detailed results from AP02 Phase 1 trials in Respiratory Research; data support Avalyn’s approach of delivering antifibrotic medicines directly to the lungs
Get started
Create a free account to read the full story.